5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021) - Gligorov, J.; Pivot, X.; Ataseven, B.; De Laurentiis, M.; Llombart, A.; Jung, K.H.; Manikhas, A.; Azim, H.A.; Alexandrou, A.; Gupta, K.; Herraez-Baranda, L.; Tosti, N.; et al.